-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
-
- Our Pipeline Development
-
Nu.Q® Cancer
We are developing a range of blood-based assays with potential applications beyond cancer detection.
-
Capture-Seq™
We have developed Capture-Seq™, a novel liquid biopsy method designed to isolate and analyze pure circulating tumor-derived DNA (ctDNA) from blood samples.
New Study Highlights Elevated Circulating Nucleosome Levels Following Traumatic Injury
- Share
- Tweet
- Share on Facebook
- Share
A recent study published in the journal Shock investigated circulating nucleosome levels in patients following traumatic injury using the Nu.Q® H3.1 and Nu.Q® H3R8 Cit assays.
The pilot study, titled “Quantification of Circulating Nucleosomes Using Novel Assays Shows Elevated Levels in Patients After Traumatic Injury,” analyzed plasma samples from more than 500 trauma patients and found significantly elevated nucleosome concentrations compared to healthy controls. Researchers also observed higher levels in patients who later developed venous thromboembolism (VTE), highlighting the potential relevance of nucleosome biomarkers in trauma and critical care settings.
The findings add to the growing body of evidence supporting the role of circulating nucleosomes as biomarkers of inflammation, tissue injury, and disease severity.
Read the full paper here: Shock Journal publication
Related Articles
-
Poster & Publications
Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
-
Press Releases
Volition Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields
